195 related articles for article (PubMed ID: 29477057)
21. Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
Arai J; Niikura R; Hayakawa Y; Kawahara T; Honda T; Hasatani K; Yoshida N; Nishida T; Sumiyoshi T; Kiyotoki S; Ikeya T; Arai M; Suzuki N; Tsuji Y; Yamada A; Kawai T; Koike K
Digestion; 2022; 103(3):192-204. PubMed ID: 34929693
[TBL] [Abstract][Full Text] [Related]
22. Haemochromatosis and gastrointestinal cancer.
Lagergren K; Wahlin K; Mattsson F; Alderson D; Lagergren J
Int J Cancer; 2016 Oct; 139(8):1740-3. PubMed ID: 27300578
[TBL] [Abstract][Full Text] [Related]
23. Oral disease and risk of oesophageal and gastric cancer in a nationwide nested case-control study in Sweden.
Ljung R; Martin L; Lagergren J
Eur J Cancer; 2011 Sep; 47(14):2128-32. PubMed ID: 21489778
[TBL] [Abstract][Full Text] [Related]
24. Incidence trends in oesophageal cancer by histological type: An updated analysis in Sweden.
Xie SH; Mattsson F; Lagergren J
Cancer Epidemiol; 2017 Apr; 47():114-117. PubMed ID: 28258029
[TBL] [Abstract][Full Text] [Related]
25. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.
Vaughan TL; Farrow DC; Hansten PD; Chow WH; Gammon MD; Risch HA; Stanford JL; Schoenberg JB; Mayne ST; Rotterdam H; Dubrow R; Ahsan H; West AB; Blot WJ; Fraumeni JF
Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):749-56. PubMed ID: 9752982
[TBL] [Abstract][Full Text] [Related]
26. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia.
Lagergren J; Bergström R; Lindgren A; Nyrén O
Int J Cancer; 2000 Feb; 85(3):340-6. PubMed ID: 10652424
[TBL] [Abstract][Full Text] [Related]
27. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
28. Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis.
Molina-Infante J; van Rhijn BD
Best Pract Res Clin Gastroenterol; 2015 Oct; 29(5):749-758. PubMed ID: 26552774
[TBL] [Abstract][Full Text] [Related]
29. Familial risk for esophageal cancer: an updated epidemiologic study from Sweden.
Ji J; Hemminki K
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):840-5. PubMed ID: 16678496
[TBL] [Abstract][Full Text] [Related]
30. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study.
Chien LN; Huang YJ; Shao YH; Chang CJ; Chuang MT; Chiou HY; Yen Y
Int J Cancer; 2016 Mar; 138(6):1401-9. PubMed ID: 26488896
[TBL] [Abstract][Full Text] [Related]
31. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
32. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma.
Ye W; Chow WH; Lagergren J; Boffetta P; Boman G; Adami HO; Nyrén O
Br J Cancer; 2001 Nov; 85(9):1317-21. PubMed ID: 11720467
[TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts.
De Jonge PJ; Siersema PD; Van Breda SG; Van Zoest KP; Bac DJ; Leeuwenburgh I; Ouwendijk RJ; Van Dekken H; Kusters JG; Kuipers EJ
Aliment Pharmacol Ther; 2008 Jul; 28(1):127-36. PubMed ID: 18384663
[TBL] [Abstract][Full Text] [Related]
34. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
35. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
36. Motor vehicle exposure and risk of oesophageal adenocarcinoma.
Lagergren J; Jansson C; Lu Y
Eur J Cancer; 2011 Jul; 47(10):1446-9. PubMed ID: 21570825
[TBL] [Abstract][Full Text] [Related]
37. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms.
Triadafilopoulos G; Zikos T; Regalia K; Sonu I; Fernandez-Becker NQ; Nguyen L; Nandwani MCR; Clarke JO
Dig Dis Sci; 2018 Oct; 63(10):2673-2680. PubMed ID: 29959725
[TBL] [Abstract][Full Text] [Related]
38. Characterizing Potentially Inappropriate Prescribing of Proton Pump Inhibitors in Older People in Primary Care in Ireland from 1997 to 2012.
Moriarty F; Bennett K; Cahir C; Fahey T
J Am Geriatr Soc; 2016 Dec; 64(12):e291-e296. PubMed ID: 27996115
[TBL] [Abstract][Full Text] [Related]
39. Risk of oesophageal cancer by histology among patients hospitalised for gastroduodenal ulcers.
Bahmanyar S; Zendehdel K; Nyrén O; Ye W
Gut; 2007 Apr; 56(4):464-8. PubMed ID: 17005761
[TBL] [Abstract][Full Text] [Related]
40. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Gyawali CP
Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
